Nasdaq notifies 60 Degrees Pharmaceuticals of delisting for bid price rule violation

60 DEGREES PHARMACEUTICALS, INC.

Nasdaq determined common stock failed $1.00 minimum bid price for 30 consecutive business days.
Company ineligible for compliance period due to 1-for-5 reverse stock split on Feb 24, 2025.
Warrants also subject to delisting under Nasdaq Listing Rule 5560(a).
Company paid $20,000 hearing fee and appealed, staying suspension pending panel decision.
No assurance the Nasdaq Panel will grant continued listing.

item 3.01item 7.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.